bi 1358894
Small moleculeexperimental
Clinical trial activity
17 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started Jul 18, 2017 (NCT03210272)
Timeline
Indications
Mechanism of action
TRPC5 inhibitor
TRPC4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05934942 | Phase 1 | Sep 8, 2023 | Boehringer Ingelheim |
| NCT05155306 | Phase 1 | Jan 14, 2022 | Boehringer Ingelheim |
| NCT05103657 | Phase 2 | Dec 6, 2021 | Boehringer Ingelheim |
| NCT04899674 | Phase 1 | Jun 30, 2021 | Boehringer Ingelheim |
| NCT04521478 | Phase 2 | Nov 20, 2020 | Boehringer Ingelheim |
| NCT04566601 | Phase 2 | Nov 13, 2020 | Boehringer Ingelheim |
| NCT04567316 | Phase 1 | Oct 19, 2020 | Boehringer Ingelheim |
| NCT04426851 | Phase 1 | Jul 8, 2020 | Boehringer Ingelheim |
| NCT04423757 | Phase 2 | Jun 22, 2020 | Boehringer Ingelheim |
| NCT04099732 | Phase 1 | Oct 7, 2019 | Boehringer Ingelheim |
| NCT03904576 | Phase 1 | Apr 18, 2019 | Boehringer Ingelheim |
| NCT03892616 | Phase 1 | Apr 8, 2019 | Boehringer Ingelheim |
| NCT03875001 | Phase 1 | Mar 25, 2019 | Boehringer Ingelheim |
| NCT03843151 | Phase 1 | Mar 19, 2019 | Boehringer Ingelheim |
| NCT03854578 | Phase 1 | Mar 12, 2019 | Boehringer Ingelheim |
| NCT03754959 | Phase 1 | Dec 18, 2018 | Boehringer Ingelheim |
| NCT03210272 | Phase 1 | Jul 18, 2017 | Boehringer Ingelheim |
Showing 17 of 17 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 17 | 17 | 2 | 2017 |
1 organizations
Page 1 / 1